Oncogene-induced senescence in pituitary adenomas and carcinomas.

Oncogene-induced senescence in pituitary adenomas and carcinomas.

OBJECTIVE: The model of "oncogene-induced senescence" (OIS), resulting in cell-proliferation arrest, has recently been suggested as a possible explanation for the non-progression of pituitary tumours to malignancy. The aim of the study was to compare the expression of β-galactosidase as a...

Full description

Bibliographic Details
Main Authors:	Alexandraki, K, Munayem Khan, M, Chahal, H, Dalantaeva, N, Trivellin, G, Berney, D, Caron, P, Popovic, V, Pfeifer, M, Jordan, S, Korbonits, M, Grossman, AB
Format:	Journal article
Language:	English
Published:	2012

Similar Items

The Pathogenic Role of AIP Mutations - The Importance of the Integration of Clinical, Experimental and Modeling Data on Advising Patients and Their Families with Pituitary Adenoma Predisposition.
by: Trivellin, G, et al.
Published: (2010)

A mutation and expression analysis of the oncogene BRAF in pituitary adenomas.
by: Ewing, I, et al.
Published: (2007)

MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro.
by: Trivellin, G, et al.
Published: (2012)

Novel molecular aspects of pituitary adenomas.
by: Hubina, E, et al.
Published: (2005)

Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA).
by: Chahal, H, et al.
Published: (2010)

The pathology of pituitary adenomas from a clinical perspective.
by: Dworakowska, D, et al.
Published: (2011)

Leptin in pituitary adenomas--a novel paracrine regulatory system.
by: Korbonits, M, et al.
Published: (2001)

Differential gene expression in pituitary adenomas by oligonucleotide array analysis.
by: Morris, D, et al.
Published: (2005)

The pathophysiology of pituitary adenomas.
by: Dworakowska, D, et al.
Published: (2009)

Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families.
by: Igreja, S, et al.
Published: (2010)

AIP mutation in pituitary adenomas in the 18th century and today.
by: Chahal, H, et al.
Published: (2011)

Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
by: Garcia, E, et al.
Published: (2013)

Brief Report: AIP Mutation in Pituitary Adenomas in the 18th Century and Today.
by: Chahal, H, et al.
Published: (2011)

Akting and cycling: a tale of the pituitary.
by: Grossman, AB, et al.
Published: (2004)

Pituitary-targeted medical therapy of Cushing's disease
by: Alexandraki, K, et al.
Published: (2008)

Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei.
by: Pyle, M, et al.
Published: (2003)

Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort.
by: Preda, V, et al.
Published: (2014)

Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.
by: Morris, D, et al.
Published: (2003)

The release of leptin and its effect on hormone release from human pituitary adenomas.
by: Korbonits, M, et al.
Published: (2001)

Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas
by: C.B. Murat, et al.
Published: (2012-09-01)

Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas
by: C.B. Murat, et al.
Published: (2012-09-01)

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
by: Korbonits, M, et al.
Published: (1998)

Cyclin D and cyclin E expression in normal and adenomatous pituitary.
by: Jordan, S, et al.
Published: (2000)

Cyclins and their related proteins in pituitary tumourigenesis.
by: Muşat, M, et al.
Published: (2010)

Temozolomide in aggressive pituitary adenomas and carcinomas
by: Leon D. Ortiz, et al.
Published: (2012-01-01)

Pituitary adenoma surgery survey: neurosurgical centers and pituitary adenomas
by: D. Netuka, et al.
Published: (2022-01-01)

Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas.
by: Simpson, D, et al.
Published: (2001)

Presence of ghrelin in normal and adenomatous human pituitary.
by: Korbonits, M, et al.
Published: (2001)

Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
by: Chahal, H, et al.
Published: (2012)

Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors.
by: Korbonits, M, et al.
Published: (2001)

Pituitary chondrosarcoma: an unusual cause of a sellar mass presenting as a pituitary adenoma.
by: Allan, C, et al.
Published: (2001)

The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.
by: Leontiou, C, et al.
Published: (2008)

The Epigenomics of Pituitary Adenoma
by: Blake M. Hauser, et al.
Published: (2019-05-01)

Hexarelin as a test of pituitary reserve in patients with pituitary disease.
by: Korbonits, M, et al.
Published: (1999)

Role of regulatory factors in pituitary tumour formation.
by: Korbonits, M, et al.
Published: (2004)

Angiogenesis in pituitary adenomas and the normal pituitary gland.
by: Turner, H, et al.
Published: (2000)

Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
by: Vax, V, et al.
Published: (2003)

Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review
by: Congxin Dai, et al.
Published: (2021-11-01)

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
by: Dworakowska, D, et al.
Published: (2009)

Cell cycle dysregulation in pituitary oncogenesis.
by: Muşat, M, et al.
Published: (2004)